iqvia prescriptions semaglutide tirzepatide q3 2024 IQVIA - New weight loss injection 2026 Q3 2024 IQVIA Prescriptions: Semaglutide and Tirzepatide Show Strong Q3 2024 Performance and Future Outlook

New weight loss injection 2026 The landscape of obesity and diabetes management is rapidly evolving, with groundbreaking medications like semaglutide and tirzepatide at the forefront.q3 2024 earnings call Analyzing prescription data from key industry players like IQVIA provides crucial insights into market trendsGLP-1s - What We Know Right Now, For Now (Part 1). As of Q3 2024, these two glucagon-like peptide-1 (GLP-1) based therapies have demonstrated significant growth and are poised for continued expansion in the coming years.

Data emerging from IQVIA indicates robust prescription volumes for both semaglutide and tirzepatide through Q3 2024. This period saw continued strong demand, building on the momentum established in earlier quarters. The search_keyword "iqvia prescriptions semaglutide tirzepatide q3 2024" reflects a keen interest in understanding the performance of these pivotal drugs within the current market.Non-Traditional Channels: The Compounded GLP-1 Market

A significant development for tirzepatide was its removal from the FDA drug shortage list in December 2024, with semaglutide expected to follow in early 2025. Despite past shortages, the compounded market for these drugs has seen a rise, with some analyses even noting "The Tirzepatide Shock" of late 2024, underscoring the impactful introduction and subsequent demand for these treatments. Semaglutide prescriptions, for instance, have seen a dramatic surge, climbing from 0.7 million in June 2021 to a remarkable 2.Massive sales for weight loss drugs spur Eli Lilly's Q36 million by February 2024.

Looking ahead, projections for 2025 and beyond paint a consistently optimistic picture for semaglutide and tirzepatide.q3 2024 earnings call Label expansions for both drugs are anticipated in 2025, further solidifying their position in treating the whole-body health of patients. IQVIA's reports, including their "Global Use of Medicines 2024" and "Obesity Pipeline 2025" analyses, consistently highlight the transformative impact of these GLP-1 agonists2024: The obesity market's inflection point?. Furthermore, IQVIA's latest usage and spending trends forecast a substantial growth in the US obesity market, projecting it to reach $35 billion by 2028, largely driven by these two leading therapiesThe Use of Medicines in the U.S.2024. May2024. Affiliation:IQVIA. Authors ... (semaglutide) injection 2.4 mg supply. Jan2024. Novo Nordisk. Novo Nordisk ....

The market performance of these drugs is not confined to volume alone. In Q3 2025 presentations, companies like Eli Lilly have indicated substantial revenue growth driven by tirzepatide (sold as Mounjaro for diabetes and Zepbound for obesity), exceeding $10 billion in the third quarter. Similarly, semaglutide, marketed as Ozempic and Wegovy by Novo Nordisk, has been a significant revenue driver. One analysis suggests that from June to September 2025, overall semaglutide prescriptions increased by 2.01%, while tirzepatide saw an even more impressive rise of 8.36%.

The search intent behind queries related to these drugs often encompasses inquiries about medications, prescriptions, and market data from sources like IQVIA2024年5月7日—IQVIA'slatest usage and spending trends report forecasts US obesity market will grow to bn by 2028, while the two leading GLP-1 agonists .... The market for anti-obesity medications (AOMs) is projected to surpass $30 billion in 2024, with the widespread rollout of Novo Nordisk's semaglutide and Eli Lilly's tirzepatide being key contributors.Note: the estimated GLP-1 share ofprescriptionsis based on volume packs fromIQVIA. ... 1) Figure has been restated from 17 inQ3 2024Company announcement to ...

Beyond their primary indications, semaglutide has also gained FDA approval to reduce the risk of cardiovascular death, heart attack, and stroke in adults with pre-existing cardiovascular disease.2025年5月8日—Leading the way are two marketed drugs — Novo Nordisk's Ozempic/Wegovy (semaglutide) and Eli Lilly's Mounjaro/Zepbound (tirzepatide) — which ... This expansion of therapeutic benefits further underscores their importance in patient care.2024年5月1日—Key drug shortages include in the oncology space (cisplatin and carboplatin), antibiotics (amoxicillin), GLP-1s (semaglutide[Ozempic], ... While tirzepatide provided 47% greater relative weight loss compared to semaglutide in some comparative analyses, both drugs are critically important in the management of overweight and obesity.Drugs | Top 10 2024

The evolving market dynamics are also reflected in related searches, including "IQVIA GLP-1," "Semaglutide 2025," and "New weight loss injection 2026." The continued innovation and strong prescription trends observed through Q3 2024 suggest that semaglutide and tirzepatide will remain central pillars in the treatment of metabolic diseases for the foreseeable future. The accurate reporting and analysis of pharmacy data by entities like IQVIA are indispensable for stakeholders seeking to understand and navigate this dynamic therapeutic area. As the market matures, understanding nuanced prescription trends and future market outlook will be crucial.